Navigation Links
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
Date:4/21/2009

- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research -

- University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented -

MALVERN, Pa., April 21 /PRNewswire/ -- Ascenta Therapeutics announced today that the results of preclinical studies of its orally-active, small molecule, pro-apoptotic agent, AT-406, have been presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR), in Denver, Colorado (Abstract # 1917).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO )

The studies demonstrated that AT-406 was active as a single agent in vitro in a number of cell lines, including breast cancer, lung cancer, pancreatic cancer, prostate cancer, and bladder cancer, and in several mouse xenograft cancer models. AT-406 also showed synergistic or additive effects when used together with tyrosine kinase inhibitors or chemotherapy in vitro in those cell lines.

"AT-406 is the second agent in our development pipeline to demonstrate broad anti-cancer activity in pre-clinical models, including synergy with other agents, by targeting a specific apoptotic pathway," said Mel Sorensen, MD, CEO of Ascenta Therapeutics. "On the basis of these encouraging data, we plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to allow us to begin human clinical trials with AT-406 later this year."

About AT-406

AT-406 is an orally-active, small molecule drug designed to promote programmed cell death (apoptosis) in tumor cells by blocking the activity of at least three "inhibitors of apoptosis proteins" or IAPs (including XIAP, c-IAP1, and c-IAP2) to create conditions in which apoptosis can proceed. As such, AT-406 is considered a multi-IAP antagonist. IAPs are key components of the complex cascade of protein signaling that activates enzymes called caspases to initiate breakdown of the cancer cell. AT-406 is thought to mimic the activity of Smac (second mitochondria-derived activator of caspases) by binding to XIAP and preventing it from inhibiting caspase activation. Upon binding, AT-406 induces rapid degradation of cIAP-1/2 proteins and promotes apoptosis through activation of caspase-8 and the death-receptor complex.

AT-406 is in late-stage preclinical development and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to work synergistically with conventional chemotherapeutic and targeted agents (such as tyrosine kinase inhibitors) in preclinical tumor models.

Other Research Including AT-101

Ascenta Therapeutics also announced that researchers from the University of Pennsylvania presented results at AACR from an independent laboratory study examining the role of Bcl-2 homology (BH) family proteins in the development of chemotherapy resistance in neuroblastoma (Abstract # 3269). Using human-derived neuroblastoma cell lines, these investigators demonstrated differential resistance patterns to inhibitors of the Bcl-2 family proteins based on the relative BH proteins expressed (specifically, Mcl-1 or Bcl-2). They showed that Ascenta's small molecule pan-Bcl-2 inhibitor, AT-101, had preferential inhibition in Mcl-1 predominant lines. They concluded that compounds with activity against Mcl-1 may be useful in the treatment of high-risk neuroblastoma and warrant further study in human clinical trials.

About Ascenta Therapeutics

Ascenta Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company that discovers and develops new medicines for the treatment of cancer. The company is headquartered in Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, is focused on discovering molecules that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta's lead agent, AT-101, is an orally-active small molecule pan Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 clinical trials in castrate resistant prostate cancer. The Company's preclinical pipeline includes the oral multi-IAP antagonist AT-406, and an HDM2-p53 inhibitor program.

For additional information on Ascenta Therapeutics, please visit the company's website at www.ascenta.com


'/>"/>
SOURCE Ascenta Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
2. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
3. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
6. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
7. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
8. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
9. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
10. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
11. Arno Therapeutics Reports 2008 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Australian-US drug discovery and development ... the appointment of a new Chairman, Mr John O,Connor ... effective immediately. James Garner , has also ... and former Acting CEO, Mr Iain Ross , will ... --> James Garner , has also been formally ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at the University’s ... 20+ speakers and activities such as workshops and competitions for ample networking, ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... other cuvette manufacturers is their supercharged customer service and their extensive database of glass ... flow of inside information, they have recently revamped their manufacturing techniques to reduce lead ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):